Agios Pharmaceuticals宣布,公司计划于2026年上半年启动针对苯丙酮尿症(PKU)的药物AG-181的Ib期机制验证临床试验。该试验旨在深入评估AG-181的作用机制与疗效潜力。
若试验进展顺利,Agios将在2026年下半年确认AG-181的机制验证结果,为后续临床开发提供关键数据支持。这一里程碑将有助于进一步明确该疗法在治疗苯丙酮尿症方面的科学依据与开发前景。
Agios Pharmaceuticals宣布,公司计划于2026年上半年启动针对苯丙酮尿症(PKU)的药物AG-181的Ib期机制验证临床试验。该试验旨在深入评估AG-181的作用机制与疗效潜力。
若试验进展顺利,Agios将在2026年下半年确认AG-181的机制验证结果,为后续临床开发提供关键数据支持。这一里程碑将有助于进一步明确该疗法在治疗苯丙酮尿症方面的科学依据与开发前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.